IGF1 and Hepatic fibrosis: Through the development of a nanoparticle-based delivery system, they demonstrated that RNF41 ameliorates liver fibrosis and reduces hepatic injury by suppressing hepatic stellate cell (HSC) activation signaling while upregulating matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor-1 (IGF-1) (18).